{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:31:19Z","timestamp":1777494679749,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s12032-021-01629-0","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T20:02:59Z","timestamp":1642708979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparative expression analysis of dasatinib and ponatinib-regulated lncRNAs in chronic myeloid leukemia and their network analysis"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6797-7655","authenticated-orcid":false,"given":"Cagla","family":"Kayabasi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3058-9971","authenticated-orcid":false,"given":"Ayse","family":"Caner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunde","family":"Yilmaz Susluer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tugce","family":"Balci Okcanoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Besra","family":"Ozmen Yelken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aycan","family":"Asik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeynep","family":"Mutlu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cansu","family":"Caliskan Kurt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bakiye","family":"Goker Bagca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cigir","family":"Biray Avci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahri","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guray","family":"Saydam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cumhur","family":"Gunduz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,20]]},"reference":[{"issue":"17","key":"1629_CR1","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","volume":"340","author":"CL Sawyers","year":"1999","unstructured":"Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340(17):1330\u201340. https:\/\/doi.org\/10.1056\/NEJM199904293401706.","journal-title":"N Engl J Med"},{"issue":"6","key":"1629_CR2","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/nrc2147","volume":"7","author":"JV Melo","year":"2007","unstructured":"Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007;7(6):441\u201353. https:\/\/doi.org\/10.1038\/nrc2147.","journal-title":"Nat Rev Cancer"},{"issue":"14","key":"1629_CR3","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, et al. Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031\u20137. https:\/\/doi.org\/10.1056\/NEJM200104053441401.","journal-title":"N Engl J Med"},{"issue":"20","key":"1629_CR4","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1182\/blood-2009-05-221531","volume":"114","author":"RJ Garg","year":"2009","unstructured":"Garg RJ, Kantarjian H, O\u2019Brien S, Quintas-Cardama A, Faderl S, et al. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood. 2009;114(20):4361\u20138. https:\/\/doi.org\/10.1182\/blood-2009-05-221531.","journal-title":"Blood"},{"issue":"17","key":"1629_CR5","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1158\/1078-0432.CCR-10-2616","volume":"17","author":"JC Montero","year":"2011","unstructured":"Montero JC, Seoane S, Ocana A, Pandiella A. Inhibition of src family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res. 2011;17(17):5546\u201352. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2616.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1629_CR6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O'Hare","year":"2009","unstructured":"O\u2019Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, et al. Ap24534, a pan-bcr-abl inhibitor for chronic myeloid leukemia, potently inhibits the t315i mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16(5):401\u201312. https:\/\/doi.org\/10.1016\/j.ccr.2009.09.028.","journal-title":"Cancer Cell"},{"issue":"5830","key":"1629_CR7","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1126\/science.1138341","volume":"316","author":"P Kapranov","year":"2007","unstructured":"Kapranov P, Cheng J, Dike S, Nix DA, Duttagupta R, et al. Rna maps reveal new rna classes and a possible function for pervasive transcription. Science. 2007;316(5830):1484\u20138. https:\/\/doi.org\/10.1126\/science.1138341.","journal-title":"Science"},{"issue":"15","key":"1629_CR8","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1158\/0008-5472.CAN-16-2634","volume":"77","author":"A Bhan","year":"2017","unstructured":"Bhan A, Soleimani M, Mandal SS. Long noncoding rna and cancer: a new paradigm. Cancer Res. 2017;77(15):3965\u201381. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-2634.","journal-title":"Cancer Res"},{"issue":"8","key":"1629_CR9","doi-asserted-by":"publisher","first-page":"15386","DOI":"10.3390\/ijms140815386","volume":"14","author":"A Garitano-Trojaola","year":"2013","unstructured":"Garitano-Trojaola A, Agirre X, Prosper F, Fortes P. Long non-coding RNAs in haematological malignancies. Int J Mol Sci. 2013;14(8):15386\u2013422. https:\/\/doi.org\/10.3390\/ijms140815386.","journal-title":"Int J Mol Sci"},{"issue":"31","key":"1629_CR10","doi-asserted-by":"publisher","first-page":"50666","DOI":"10.18632\/oncotarget.9308","volume":"7","author":"L Nobili","year":"2016","unstructured":"Nobili L, Lionetti M, Neri A. Long non-coding rnas in normal and malignant hematopoiesis. Oncotarget. 2016;7(31):50666\u201381. https:\/\/doi.org\/10.18632\/oncotarget.9308.","journal-title":"Oncotarget"},{"key":"1629_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174446","volume":"910","author":"C Kayabasi","year":"2021","unstructured":"Kayabasi C, Yelken BO, Asik A, Okcanoglu TB, Sogutlu F, et al. Pi3k\/mtor dual-inhibition with vs-5584 enhances anti-leukemic efficacy of ponatinib in blasts and ph-negative lscs of chronic myeloid leukemia. Eur J Pharmacol. 2021;910: 174446. https:\/\/doi.org\/10.1016\/j.ejphar.2021.174446.","journal-title":"Eur J Pharmacol"},{"key":"1629_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/database\/baw167","author":"A Junge","year":"2017","unstructured":"Junge A, Refsgaard JC, Garde C, Pan X, Santos A, et al. Rain: Rna-protein association and interaction networks. Database (Oxford). 2017. https:\/\/doi.org\/10.1093\/database\/baw167.","journal-title":"Database (Oxford)."},{"key":"1629_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ncrna4040033","author":"K Guglas","year":"2018","unstructured":"Guglas K, Kolenda T, Teresiak A, Kopczynska M, Lasinska I, et al. lncRNA expression after irradiation and chemoexposure of HNSCC cell lines. Noncoding RNA. 2018. https:\/\/doi.org\/10.3390\/ncrna4040033.","journal-title":"Noncoding RNA"},{"issue":"2","key":"1629_CR14","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1158\/1078-0432.CCR-09-3314","volume":"17","author":"T O'Hare","year":"2011","unstructured":"O\u2019Hare T, Deininger MW, Eide CA, Clackson T, Druker BJ. Targeting the bcr-abl signaling pathway in therapy-resistant philadelphia chromosome-positive leukemia. Clin Cancer Res. 2011;17(2):212\u201321. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-3314.","journal-title":"Clin Cancer Res"},{"issue":"28","key":"1629_CR15","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1038\/sj.onc.1210179","volume":"26","author":"K Nunoda","year":"2007","unstructured":"Nunoda K, Tauchi T, Takaku T, Okabe S, Akahane D, et al. Identification and functional signature of genes regulated by structurally different abl kinase inhibitors. Oncogene. 2007;26(28):4179\u201388. https:\/\/doi.org\/10.1038\/sj.onc.1210179.","journal-title":"Oncogene"},{"key":"1629_CR16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.gene.2017.09.036","volume":"637","author":"C Kayabasi","year":"2017","unstructured":"Kayabasi C, Okcanoglu TB, Yelken BO, Asik A, Susluer SY, et al. Comparative effect of imatinib and ponatinib on autophagy and mirnome in chronic myeloid leukemia. Gene. 2017;637:173\u201380. https:\/\/doi.org\/10.1016\/j.gene.2017.09.036.","journal-title":"Gene"},{"issue":"6","key":"1629_CR17","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s11899-018-0474-6","volume":"13","author":"T Zhou","year":"2018","unstructured":"Zhou T, Medeiros LJ, Hu S. Chronic myeloid leukemia: beyond bcr-abl1. Curr Hematol Malig Rep. 2018;13(6):435\u201345. https:\/\/doi.org\/10.1007\/s11899-018-0474-6.","journal-title":"Curr Hematol Malig Rep"},{"issue":"42","key":"1629_CR18","doi-asserted-by":"publisher","first-page":"6432","DOI":"10.1038\/sj.onc.1208796","volume":"24","author":"DJ Barnes","year":"2005","unstructured":"Barnes DJ, Schultheis B, Adedeji S, Melo JV. Dose-dependent effects of bcr-abl in cell line models of different stages of chronic myeloid leukemia. Oncogene. 2005;24(42):6432\u201340. https:\/\/doi.org\/10.1038\/sj.onc.1208796.","journal-title":"Oncogene"},{"issue":"1","key":"1629_CR19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2174\/156800913804486638","volume":"13","author":"J Kuroda","year":"2013","unstructured":"Kuroda J, Shimura Y, Yamamoto-Sugitani M, Sasaki N, Taniwaki M. Multifaceted mechanisms for cell survival and drug targeting in chronic myelogenous leukemia. Curr Cancer Drug Targets. 2013;13(1):69\u201379.","journal-title":"Curr Cancer Drug Targets"},{"issue":"40","key":"1629_CR20","doi-asserted-by":"publisher","first-page":"14907","DOI":"10.1073\/pnas.0606176103","volume":"103","author":"J Kuroda","year":"2006","unstructured":"Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, et al. Bim and bad mediate imatinib-induced killing of bcr\/abl+ leukemic cells, and resistance due to their loss is overcome by a bh3 mimetic. Proc Natl Acad Sci USA. 2006;103(40):14907\u201312. https:\/\/doi.org\/10.1073\/pnas.0606176103.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"33","key":"1629_CR21","doi-asserted-by":"publisher","first-page":"53116","DOI":"10.18632\/oncotarget.10605","volume":"7","author":"S Okabe","year":"2016","unstructured":"Okabe S, Tauchi T, Tanaka Y, Sakuta J, Ohyashiki K. Combination therapy with copanlisib and abl tyrosine kinase inhibitors against philadelphia chromosome-positive resistant cells. Oncotarget. 2016;7(33):53116\u201326. https:\/\/doi.org\/10.18632\/oncotarget.10605.","journal-title":"Oncotarget"},{"key":"1629_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101544","author":"S Flis","year":"2019","unstructured":"Flis S, Bratek E, Chojnacki T, Piskorek M, Skorski T. Simultaneous inhibition of bcr-abl1 tyrosine kinase and pak1\/2 serine\/threonine kinase exerts synergistic effect against chronic myeloid leukemia cells. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11101544.","journal-title":"Cancers (Basel)."},{"issue":"9","key":"1629_CR23","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1038\/sj.cdd.4402168","volume":"14","author":"J Kuroda","year":"2007","unstructured":"Kuroda J, Kimura S, Strasser A, Andreeff M, O\u2019Reilly LA, et al. Apoptosis-based dual molecular targeting by inno-406, a second-generation bcr-abl inhibitor, and abt-737, an inhibitor of antiapoptotic bcl-2 proteins, against bcr-abl-positive leukemia. Cell Death Differ. 2007;14(9):1667\u201377. https:\/\/doi.org\/10.1038\/sj.cdd.4402168.","journal-title":"Cell Death Differ"},{"issue":"3","key":"1629_CR24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.exphem.2015.12.002","volume":"44","author":"WT Sun","year":"2016","unstructured":"Sun WT, Xiang W, Ng BL, Asari K, Bunte RM, et al. Inhibition of isoprenylcysteine carboxylmethyltransferase augments bcr-abl1 tyrosine kinase inhibition-induced apoptosis in chronic myeloid leukemia. Exp Hematol. 2016;44(3):189\u201393. https:\/\/doi.org\/10.1016\/j.exphem.2015.12.002.","journal-title":"Exp Hematol"},{"issue":"6","key":"1629_CR25","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1038\/leu.2016.34","volume":"30","author":"E Nievergall","year":"2016","unstructured":"Nievergall E, Reynolds J, Kok CH, Watkins DB, Biondo M, et al. Tgf-alpha and il-6 plasma levels selectively identify cml patients who fail to achieve an early molecular response or progress in the first year of therapy. Leukemia. 2016;30(6):1263\u201372. https:\/\/doi.org\/10.1038\/leu.2016.34.","journal-title":"Leukemia"},{"issue":"19","key":"1629_CR26","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1182\/blood-2013-02-485607","volume":"122","author":"P Gallipoli","year":"2013","unstructured":"Gallipoli P, Pellicano F, Morrison H, Laidlaw K, Allan EK, et al. Autocrine tnf-alpha production supports cml stem and progenitor cell survival and enhances their proliferation. Blood. 2013;122(19):3335\u20139. https:\/\/doi.org\/10.1182\/blood-2013-02-485607.","journal-title":"Blood"},{"issue":"4","key":"1629_CR27","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ccr.2012.02.018","volume":"21","author":"B Zhang","year":"2012","unstructured":"Zhang B, Ho YW, Huang Q, Maeda T, Lin A, et al. Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell. 2012;21(4):577\u201392. https:\/\/doi.org\/10.1016\/j.ccr.2012.02.018.","journal-title":"Cancer Cell"},{"issue":"23","key":"1629_CR28","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1182\/blood-2015-11-679985","volume":"128","author":"H Agerstam","year":"2016","unstructured":"Agerstam H, Hansen N, von Palffy S, Sanden C, Reckzeh K, et al. Il1rap antibodies block il-1-induced expansion of candidate cml stem cells and mediate cell killing in xenograft models. Blood. 2016;128(23):2683\u201393. https:\/\/doi.org\/10.1182\/blood-2015-11-679985.","journal-title":"Blood"},{"issue":"1","key":"1629_CR29","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1186\/s12885-019-5871-2","volume":"19","author":"O Herrmann","year":"2019","unstructured":"Herrmann O, Kuepper MK, Butow M, Costa IG, Appelmann I, et al. Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia. BMC Cancer. 2019;19(1):658. https:\/\/doi.org\/10.1186\/s12885-019-5871-2.","journal-title":"BMC Cancer"},{"issue":"1","key":"1629_CR30","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood.v99.1.319","volume":"99","author":"SM Graham","year":"2002","unstructured":"Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, et al. Primitive, quiescent, philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to sti571 in vitro. Blood. 2002;99(1):319\u201325. https:\/\/doi.org\/10.1182\/blood.v99.1.319.","journal-title":"Blood"},{"issue":"11","key":"1629_CR31","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","volume":"103","author":"B Calabretta","year":"2004","unstructured":"Calabretta B, Perrotti D. The biology of cml blast crisis. Blood. 2004;103(11):4010\u201322. https:\/\/doi.org\/10.1182\/blood-2003-12-4111.","journal-title":"Blood"},{"issue":"4","key":"1629_CR32","doi-asserted-by":"publisher","first-page":"503","DOI":"10.18388\/abp.2013_2014","volume":"60","author":"K Danisz","year":"2013","unstructured":"Danisz K, Blasiak J. Role of anti-apoptotic pathways activated by bcr\/abl in the resistance of chronic myeloid leukemia cells to tyrosine kinase inhibitors. Acta Biochim Pol. 2013;60(4):503\u201314.","journal-title":"Acta Biochim Pol"},{"issue":"7","key":"1629_CR33","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrc839","volume":"2","author":"I Vivanco","year":"2002","unstructured":"Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase akt pathway in human cancer. Nat Rev Cancer. 2002;2(7):489\u2013501. https:\/\/doi.org\/10.1038\/nrc839.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1629_CR34","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s13046-019-1260-6","volume":"38","author":"X Gao","year":"2019","unstructured":"Gao X, Qin T, Mao J, Zhang J, Fan S, et al. Ptenp1\/mir-20a\/pten axis contributes to breast cancer progression by regulating pten via pi3k\/akt pathway. J Exp Clin Cancer Res. 2019;38(1):256. https:\/\/doi.org\/10.1186\/s13046-019-1260-6.","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-021-01629-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-021-01629-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-021-01629-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T14:32:08Z","timestamp":1644849128000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-021-01629-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,20]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1629"],"URL":"https:\/\/doi.org\/10.1007\/s12032-021-01629-0","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,20]]},"assertion":[{"value":"9 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The local ethics committee ruled that no formal ethics approval was required in this particular case.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"29"}}